Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Invested Capital (2019 - 2025)

Maxcyte (MXCT) has disclosed Invested Capital for 6 consecutive years, with $180.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 15.48% to $180.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $180.3 million, a 15.48% decrease, with the full-year FY2024 number at $206.3 million, down 11.16% from a year prior.
  • Invested Capital was $180.3 million for Q3 2025 at Maxcyte, down from $190.7 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $264.1 million in Q3 2021 to a low of $78.8 million in Q2 2021.
  • A 5-year average of $216.2 million and a median of $232.2 million in 2023 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: surged 691.26% in 2021, then fell 15.48% in 2025.
  • Maxcyte's Invested Capital stood at $262.9 million in 2021, then decreased by 3.4% to $254.0 million in 2022, then decreased by 8.58% to $232.2 million in 2023, then dropped by 11.16% to $206.3 million in 2024, then decreased by 12.59% to $180.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Invested Capital are $180.3 million (Q3 2025), $190.7 million (Q2 2025), and $199.4 million (Q1 2025).